44 Tillman Tillman E.J. E.J. Rolph Rolph T. T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases Front Endocrinol (Lausanne) Front Endocrinol (Lausanne) 11 11 2020 2020 601290 601290 33381084 33381084. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.